CYTOSORBENTS CORPORATION Cost of Revenue
CYTOSORBENTS CORPORATION (CTSO) reported Cost of Revenue of $2.58 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-06
- CYTOSORBENTS CORPORATION cost of goods and services sold for the quarter ending 2026-06-30 was $2.58M, a 7.81% decline year-over-year.
- CYTOSORBENTS CORPORATION cost of goods and services sold for the quarter ending 2026-03-31 was $2.73M, a 8.49% increase year-over-year.
- CYTOSORBENTS CORPORATION cost of goods and services sold for the quarter ending 2025-12-31 was $2.43M, a 16.09% decline year-over-year.
- CYTOSORBENTS CORPORATION cost of goods and services sold for the quarter ending 2025-09-30 was $2.82M, a 16.03% decline year-over-year.
- CYTOSORBENTS CORPORATION cost of goods and services sold for fiscal 2025 was $10.57M, a 1.27% decline from fiscal 2024.
- CYTOSORBENTS CORPORATION cost of goods and services sold for fiscal 2024 was $10.71M, a 17.26% increase from fiscal 2023.
- CYTOSORBENTS CORPORATION cost of goods and services sold for fiscal 2023 was $9.13M, a 34.57% decline from fiscal 2022.
- CYTOSORBENTS CORPORATION cost of goods and services sold for fiscal 2022 was $13.96M, a 26.33% increase from fiscal 2021.
USD
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 3 month as first filed | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 6 month as first filed | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 9 month as first filed | Cost of Goods and Services Sold 12 month | Cost of Goods and Services Sold 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.58M 10-Q · filed 2026-08-06 | $5.32M 10-Q · filed 2026-08-06 | $7.75M derived: sum of 3 quarters · filed 2026-08-06 | $10.57M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $2.73M 10-Q · filed 2026-05-13 | $5.16M derived: sum of 2 quarters · filed 2026-05-13 | $7.98M derived: sum of 3 quarters · filed 2026-05-13 | $10.79M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $2.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.25M derived: sum of 2 quarters · filed 2026-03-30 | $8.05M derived: sum of 3 quarters · filed 2026-08-06 | $10.57M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $2.82M 10-Q · filed 2025-11-13 | $5.62M derived: sum of 2 quarters · filed 2026-08-06 | $8.14M 10-Q · filed 2025-11-13 | $11.04M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $2.80M 10-Q · filed 2026-08-06 | $5.32M 10-Q · filed 2026-08-06 | $8.22M derived: sum of 3 quarters · filed 2026-08-06 | $11.58M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $2.52M 10-Q · filed 2026-05-13 | $2.52M 10-Q · filed 2025-05-14 | $5.42M derived: sum of 2 quarters · filed 2026-05-13 | $8.77M derived: sum of 3 quarters · filed 2026-05-13 | $11.11M derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $2.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $6.25M derived: sum of 2 quarters · filed 2026-03-30 | $8.59M derived: sum of 3 quarters · filed 2026-03-30 | $10.71M 10-K · filed 2026-03-30 | $10.47M 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $3.36M 10-Q · filed 2025-11-13 | $4.11M 10-Q · filed 2024-11-07 | $5.70M derived: sum of 2 quarters · filed 2025-11-13 | $7.81M 10-Q · filed 2025-11-13 | $10.72M 10-Q · filed 2024-11-07 | $6.34M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $2.34M 10-Q · filed 2025-08-07 | $3.39M 10-Q · filed 2024-08-13 | $4.46M 10-Q · filed 2025-08-07 | $6.61M 10-Q · filed 2024-08-13 | $2.99M derived: sum of 3 quarters · filed 2025-08-07 | $6.19M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $2.12M 10-Q · filed 2025-05-14 | $3.22M 10-Q · filed 2024-05-09 | $647.21K derived: sum of 2 quarters · filed 2025-05-14 | $3.85M derived: sum of 3 quarters · filed 2025-05-14 | $7.25M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | -$1.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.74M derived: sum of 2 quarters · filed 2025-03-31 | $5.14M derived: sum of 3 quarters · filed 2025-03-31 | $9.13M 10-K · filed 2025-03-31 | $13.96M 10-K · filed 2024-03-15 | |||
| 2023-09-30 | $3.20M 10-Q · filed 2024-11-07 | $6.61M derived: sum of 2 quarters · filed 2024-11-07 | $10.60M 10-Q · filed 2024-11-07 | $14.23M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | $3.40M 10-Q · filed 2024-08-13 | $7.40M 10-Q · filed 2024-08-13 | $11.03M derived: sum of 3 quarters · filed 2024-08-13 | $15.52M derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $3.99M 10-Q · filed 2024-05-09 | $7.63M derived: sum of 2 quarters · filed 2024-05-09 | $12.12M derived: sum of 3 quarters · filed 2024-05-09 | $15.67M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $8.13M derived: sum of 2 quarters · filed 2024-03-15 | $11.68M derived: sum of 3 quarters · filed 2024-03-15 | $13.96M 10-K · filed 2024-03-15 | ||||
| 2022-09-30 | $4.49M 10-Q · filed 2023-11-09 | $8.04M derived: sum of 2 quarters · filed 2023-11-09 | $10.32M 10-Q · filed 2023-11-09 | $13.45M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2022-06-30 | $3.55M 10-Q · filed 2023-08-01 | $5.83M 10-Q · filed 2023-08-01 | $8.95M derived: sum of 3 quarters · filed 2024-03-15 | $11.41M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2022-03-31 | $2.28M 10-Q · filed 2023-05-02 | $5.40M derived: sum of 2 quarters · filed 2024-03-15 | $7.86M derived: sum of 3 quarters · filed 2024-03-15 | $10.57M derived: sum of 4 quarters · filed 2024-03-15 | ||||
| 2021-12-31 | $3.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $5.59M derived: sum of 2 quarters · filed 2024-03-15 | $8.30M derived: sum of 3 quarters · filed 2024-03-15 | $11.05M 10-K · filed 2024-03-15 | ||||
| 2021-09-30 | $2.46M 10-Q · filed 2022-11-03 | $5.17M derived: sum of 2 quarters · filed 2022-11-03 | $7.92M 10-Q · filed 2022-11-03 | $10.45M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2021-06-30 | $2.71M 10-Q · filed 2022-08-02 | $5.46M 10-Q · filed 2022-08-02 | $7.99M derived: sum of 3 quarters · filed 2023-03-09 | $10.88M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2021-03-31 | $2.75M 10-Q · filed 2022-05-03 | $5.28M derived: sum of 2 quarters · filed 2023-03-09 | $8.17M derived: sum of 3 quarters · filed 2023-03-09 | $11.42M derived: sum of 4 quarters · filed 2023-03-09 | ||||
| 2020-12-31 | $2.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $5.42M derived: sum of 2 quarters · filed 2023-03-09 | $8.67M derived: sum of 3 quarters · filed 2023-03-09 | $11.05M 10-K · filed 2023-03-09 | ||||
| 2020-09-30 | $2.89M 10-Q · filed 2021-11-04 | $6.14M derived: sum of 2 quarters · filed 2021-11-04 | $8.52M 10-Q · filed 2021-11-04 | $10.62M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2020-06-30 | $3.25M 10-Q · filed 2021-08-03 | $5.63M 10-Q · filed 2021-08-03 | $7.73M derived: sum of 3 quarters · filed 2022-03-10 | $9.43M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2020-03-31 | $2.38M 10-Q · filed 2021-05-04 | $4.48M derived: sum of 2 quarters · filed 2022-03-10 | $6.18M derived: sum of 3 quarters · filed 2022-03-10 | $8.01M derived: sum of 4 quarters · filed 2022-03-10 | ||||
| 2019-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $3.79M derived: sum of 2 quarters · filed 2022-03-10 | $5.63M derived: sum of 3 quarters · filed 2022-03-10 | $7.36M 10-K · filed 2022-03-10 | ||||
| 2019-09-30 | $1.70M 10-Q · filed 2020-11-04 | $3.53M derived: sum of 2 quarters · filed 2020-11-04 | $5.27M 10-Q · filed 2020-11-04 | $7.35M derived: sum of 4 quarters · filed 2021-03-09 | ||||
| 2019-06-30 | $1.83M 10-Q · filed 2020-08-04 | $3.57M 10-Q · filed 2020-08-04 | $5.66M derived: sum of 3 quarters · filed 2021-03-09 | $7.71M derived: sum of 4 quarters · filed 2021-03-09 | ||||
| 2019-03-31 | $1.74M 10-Q · filed 2020-05-05 | $3.82M derived: sum of 2 quarters · filed 2021-03-09 | $5.87M derived: sum of 3 quarters · filed 2021-03-09 | $7.66M derived: sum of 4 quarters · filed 2021-03-09 | ||||
| 2018-12-31 | $2.08M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $4.14M derived: sum of 2 quarters · filed 2021-03-09 | $5.92M derived: sum of 3 quarters · filed 2021-03-09 | $7.49M 10-K · filed 2021-03-09 | ||||
| 2018-09-30 | $2.05M 10-Q · filed 2019-11-05 | $3.84M derived: sum of 2 quarters · filed 2019-11-05 | $5.41M 10-Q · filed 2019-11-05 | $6.67M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-06-30 | $1.79M 10-Q · filed 2019-08-06 | $3.35M 10-Q · filed 2019-08-06 | $4.62M derived: sum of 3 quarters · filed 2020-03-05 | $6.14M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-03-31 | $1.57M 10-Q · filed 2019-05-07 | $2.83M derived: sum of 2 quarters · filed 2020-03-05 | $4.35M derived: sum of 3 quarters · filed 2020-03-05 | $5.83M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2017-12-31 | $1.27M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $2.78M derived: sum of 2 quarters · filed 2020-03-05 | $4.26M derived: sum of 3 quarters · filed 2020-03-05 | $5.52M 10-K · filed 2020-03-05 | ||||
| 2017-09-30 | $1.52M 10-Q · filed 2018-11-06 | $3.00M derived: sum of 2 quarters · filed 2018-11-06 | $4.25M 10-Q · filed 2018-11-06 | |||||
| 2017-06-30 | $1.48M 10-Q · filed 2018-08-02 | $2.74M 10-Q · filed 2018-08-02 | ||||||
| 2016-12-31 | $3.95M 10-K · filed 2019-03-07 |
USN
| Period end | Cost of Goods and Services Sold 6 month |
|---|---|
| 2023-06-30 | 200.00K USN 10-Q · filed 2023-08-01 |
| 2022-06-30 | 87.00K USN 10-Q · filed 2023-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |